Evidence map›Paper›PMID 32581831›Full record

ArticleFrontiers in physiology2020

Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease.

Anna M D Watson, Eleanor A M Gould, Sarah C Moody, Priyadharshini Sivakumaran, Karly C Sourris, Bryna S M Chow, Audrey Koïtka-Weber, Terri J Allen, Karin A M Jandeleit-Dahm, Mark E Cooper and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Anna M D WatsonCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Eleanor A M GouldBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Sarah C MoodyBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Priyadharshini SivakumaranBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Karly C SourrisCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Bryna S M ChowCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Audrey Koïtka-WeberCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Terri J AllenCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Karin A M Jandeleit-DahmCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Mark E CooperCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Anna C CalkinCentral Clinical School, Monash University, Melbourne, VIC, Australia.
Baker Heart and Diabetes Institute · AUMonash University · AUDeutsches Diabetes-Zentrum e.V. · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well established that diabetes is the major cause of chronic kidney disease worldwide. Both hyperglycemia, and more recently, advanced glycation endproducts, have been shown to play critical roles in the development of kidney disease. Moreover, the renin-angiotensin system along with growth factors and cytokines have also been shown to contribute to the onset and progression of diabetic kidney disease; however, the role of lipids in this context is poorly characterized. The current study aimed to compare the effect of 20 weeks of streptozotocin-induced diabetes or western diet feeding on kidney disease in two different mouse strains, C57BL/6 mice and hyperlipidemic apolipoprotein (apo) E knockout (KO) mice. Mice were fed a chow diet (control), a western diet (21% fat, 0.15% cholesterol) or were induced with streptozotocin-diabetes (55 mg/kg/day for 5 days) then fed a chow diet and followed for 20 weeks. The induction of diabetes was associated with a 3-fold elevation in glycated hemoglobin and an increase in kidney to body weight ratio regardless of strain (

Indexed as

albuminuriacholesteroldiabeteslipidsrenal disease

Identifiers

PMID32581831
PMCPMC7283908
OpenAlexW3033453357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.